GW&K Investment Management’s Haemonetics HAE Stock Holding History

GW&K Investment Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-85	Closed	-$7K	–	1026
2025 Q4	$7K	Hold	85	–	–	﹤0.01%	901
2025 Q3	$4K	Hold	85	–	–	﹤0.01%	934
2025 Q2	$6K	Hold	85	–	–	﹤0.01%	901
2025 Q1	$5K	Hold	85	–	–	﹤0.01%	906
2024 Q4	$7K	Hold	85	–	–	﹤0.01%	842
2024 Q3	$7K	Hold	85	–	–	﹤0.01%	834
2024 Q2	$7K	Hold	85	–	–	﹤0.01%	803
2024 Q1	$7K	Hold	85	–	–	﹤0.01%	788
2023 Q4	$7K	Hold	85	–	–	﹤0.01%	783
2023 Q3	$8K	Buy	+85	New	+$7.59K	﹤0.01%	672
2023 Q1	–	Sell	-16	Closed	-$1K	–	524
2022 Q4	$1K	Buy	+16	New	+$1.29K	﹤0.01%	424
2021 Q3	–	Sell	-70	Closed	-$5K	–	391
2021 Q2	$5K	Sell	70 -41	-37%	-$2.9K	﹤0.01%	392
2021 Q1	$12K	Sell	111 -296,240	-100%	-$36.7M	﹤0.01%	365
2020 Q4	$35.2M	Buy	296,351 +239	+0.1%	+$25.7K	0.37%	121
2020 Q3	$25.8M	Buy	296,112 +25,866	+10%	+$2.26M	0.34%	124
2020 Q2	$24.2M	Buy	+270,246	New	+$27.3M	0.34%	132

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GW&K Investment Management's HAE Position: Q1 2026 in Review

GW&K Investment Management sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 85 shares — an estimated $7K sold.

GW&K Investment Management first reported a position in HAE in Q2 2020 and held it in 16 quarters. The position peaked at $35.2M in Q4 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

GW&K Investment Management reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
GW&K Investment Management sold 85 Haemonetics shares in Q1 2026, an estimated $7K.
GW&K Investment Management first reported a position in Haemonetics in Q2 2020 and held it in 16 quarters.
GW&K Investment Management's Haemonetics position peaked at $35.2M in Q4 2020.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.